



## Notice of Half Year Results

September 3, 2018

Released : September 03, 2018 07:00

RNS Number : 4933Z  
MaxCyte, Inc.  
03 September 2018

MaxCyte, Inc.

("MaxCyte" or the "Company")

### Notice of Half Year Results

**Gaithersburg, MD - 03 September 2018:** MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, will announce its interim results for the six months ended 30 June 2018 on Monday 24 September 2018.

Doug Doerfler, Chief Executive Officer, will host a presentation and live conference call for analysts at 11:00 BST on the day of the results at the offices of Panmure Gordon, 1 New Change, London EC4M 9AF.

#### **About MaxCyte**

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full

potential of their products.

For more information, visit [www.maxcyte.com](http://www.maxcyte.com).

###

For further information, please contact:

**MaxCyte Inc.**

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

*Nominated Adviser and Broker*

**Panmure Gordon**

+44 (0)20 7886 2500

Emma Earl

Freddy Crossley

Ryan McCarthy

**Corporate Broking**

James Stearns

*Financial PR Adviser*

**Consilium Strategic Communications**

+44 (0)203 709 5700

Mary-Jane Elliott

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

Chris Welsh

Sukaina Virji

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

END

NORLMMTMBIMTRP